Daniél Vega Møller

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Javed Butler, Sanjiv J. Shah, Mark C. Petrie et al. · The Lancet · 2024 · 323 citations · Full text

Medicine, Cardiology, Pharmacology +10

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Caroline Holm Nørgaard, Sarah Friedrich, Charlotte T. Hansen et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2022 · 193 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +17

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Barry A. Borlaug, Dalane W. Kitzman, Melanie J. Davies et al. · Nature Medicine · 2023 · 188 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog

Ulrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen et al. · Diabetes Care · 2017 · 111 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype

Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug et al. · JACC Heart Failure · 2023 · 105 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +16